15.8 ng/well, respectively. The hepatobiliary disposition of Cu as measured by uptake (increase in intracellular Cu in comparison to endogenous levels) and biliary excretion (increase in Cu in wash solutions obtained from hepatocytes exposed to calcium-free versus standard buffer) was determined as a function of Cu concentration and incubation time. Generally, an increase in Cu concentration or incubation time resulted in an increase in Cu uptake and/or biliary excretion; however, the extent to which they affected Cu disposition was species dependent. L-000870810 (an anti-HIV compound whose development was halted due to an observed Cu specific toxicity in the liver and kidneys of dogs after long-term exposure) showed no effect on Cu disposition in SCRH; however, increased the biliary excretion of Cu in SCDH and SCHH. This is the first report to demonstrate the utility of SCH as a model to assess hepatobiliary disposition of Cu in an in vitro system. This article has not been copyedited and formatted. The final version may differ from this version. (Linder and Hazegh-Azam, 1996) . Intestinal absorption is the primary route by which Cu enters the body where it is subsequently transported to various tissues. The vast majority of dietary Cu intake (85%) is excreted into the bile, indicating that the liver plays an important role in Cu homeostasis through regulation of biliary excretion (Thomas et al., 1995) . CTR1 (Cu transporter 1) is the transporter involved in the hepatic uptake of Cu and is located on the basolateral membrane of hepatocytes (Lee et al., 2002; Nose et al., 2006) . Intracellular distribution of Cu is facilitated by Cu chaperones (O'Halloran and Culotta, 2000) . ATOX1 is the Cu chaperone responsible for the delivery of Cu to ATP7B where, under low intracellular Cu concentrations, ATP7B is localized in the trans-golgi network and functions to mediate the incorporation of Cu into ceruloplasmin for its subsequent excretion into blood.
Immunolocalization studies in cultured hepatocytes have shown that ATP7B may play an important role in the elimination of Cu by redistributing to apical vacuoles reminiscent of bile canaliculi, thus establishing its role in the biliary excretion of Cu (Schaefer et al., 1999; Forbes and Cox, 2000; Harada et al., 2000; Cater et al., 2006; Bartee and Lutsenko, 2007) .
The expression and localization of transport proteins involved in Cu uptake and efflux have been determined; however, few studies exist that assess the functional transport of Cu in an in vitro system. Uptake studies in mouse and rat hepatocyte suspensions indicated a transporter-mediated process with saturable kinetics (Schmitt et al., 1983; Darwish et al., 1984; McArdle et al., 1988; Bingham and McArdle, 1994) . This article has not been copyedited and formatted. The final version may differ from this version. (Dijkstra et al., 1995) . However, there are disadvantages of using either suspended hepatocytes or membrane vesicles for assessing the hepatobiliary disposition (uptake and efflux) of drugs as well as Cu. In suspended hepatocytes, the cellular architecture is disrupted and transporters that normally reside in the canalicular membrane are internalized and non-functional (Hoffmaster et al., 2004) making this model useful for assessing hepatic uptake, but not hepatic efflux. Membrane vesicles allow only the assessment of one of two processes (basolateral or canalicular transport) and do not represent a true physiological model to assess both processes. Furthermore, the rate of canalicular efflux is dependent on the intracellular concentration of a molecule, which is not obtained using membrane vesicles.
Sandwich-cultured hepatocytes (SCH) maintain many of the structural and functional attributes of hepatocytes in vivo, and have been used as an in vitro model to assess the hepatobiliary disposition (hepatic uptake, biliary efflux and biliary clearance) of drug candidates (Liu et al., 1999; Ghibellini et al., 2007) . The expression, localization and function of both key uptake and efflux transporters are maintained in SCH and it has been demonstrated that this model is an optimal system to evaluate and predict the biliary clearance, transporter-based interactions and cholestatic potential of drugs (Annaert et al., 2001; McRae et al., 2006) . In the present study, we investigated whether SCH could be used as a model system to assess the hepatobiliary disposition of Cu in rat SCH (SCRH) dog SCH (SCDH) and human SCH (SCHH). Furthermore, we evaluated whether SCH This article has not been copyedited and formatted. The final version may differ from this version. could be used as an in vitro model to predict the effect L-000870810 (an anti-HIV compound whose development was halted due to an observed Cu specific toxicity in the liver and kidneys of dogs after long-term dosing) (Vacca et al., 2007) has on hepatobiliary Cu disposition among species.
MATERIALS AND METHODS
Materials. L-000870810 was supplied by Gilead Sciences (Foster City, CA). Copper (II) sulfate (CuSO 4 ) was purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions of L-000870810 were prepared at 50 mM in 100% DMSO, aliquoted and stored at -20°C.
Stock solutions of CuSO 4 were prepared at 50, 100, and 250 mM in ultra-pure H 2 O, aliquoted and stored at -20°C.
Isolation, Plating and Maintenance of SCH from rat (SCRH). Wistar rats (250-300 g)
were anesthetized prior to portal vein cannulation. Hepatocytes were isolated in a twostep, single path, re-circulating collagenase perfusion. The liver was perfused with calcium-free Krebs-Ringer HEPES buffer containing EGTA, followed by perfusion with buffer containing collagenase type I and calcium chloride. After collagenase digestion (approximately 10 minutes), the liver was removed and immersed in ice-cold Dulbecco's Modified Eagle's Medium (DMEM). The capsule surrounding the liver was torn gently to release hepatocytes and cells were filtered through a 70-µm pore nylon membrane and centrifuged (50 x g for 2 minutes). The pellet was re-suspended in equal parts DMEM and isotonic Percoll ® and centrifuged (100 x g for 5 minutes) again to separate out nonviable cells. Subsequently, the pellet was re-suspended in DMEM and centrifuged (50 x g for 2 minutes) as a final rinse. Hepatocytes were stained with trypan blue and counted in This article has not been copyedited and formatted. The final version may differ from this version. 
Quantitation of Ceruloplasmin in SCRH Medium.
On the day of study, an aliquot of medium (500 µL) was removed from each well and reserved for ceruloplasmin analysis. The concentration of ceruloplasmin in culture medium was determined using a rat ceruloplasmin ELISA assay according to manufacturer's instructions (Life Diagnostics, West Chester, PA).
Hepatobiliary Disposition of Cu in SCH.
On the day of study, culture medium was removed from each well and replaced with 1.5 mL of dosing solution containing 50, 100
or 250 µM CuSO 4 prepared in DMEM and incubated at 37°C for 2 to 8 hours. The medium (supernatant) was aspirated from each well and the hepatocytes were washed twice with 2 mL of either ice-cold standard Hank's Balanced Salt Solution (HBSS, standard buffer) or ice-cold calcium-free HBSS (calcium-free buffer). Two milliliters of either warm (37°C) standard buffer or warm (37°C) calcium-free buffer (with 0.38 g/L EGTA) were added to the hepatocytes and incubated for 10 minutes. Following incubation, 1 mL of the medium (supernatant) was removed from each well, placed in cryovials and stored at approximately -70°C for subsequent analysis. The remaining medium was aspirated from each well and the hepatocytes were washed three times with 2 mL of ice-cold standard buffer. Subsequent to the final rinse, all wash solution was removed from each well and plates were stored at less than -70°C for Cu analysis.
The uptake and biliary excretion of taurocholate were used as a control to evaluate transporter function using the following procedure. Hepatocytes were washed three times with 2 mL of either standard or calcium-free buffer (with EGTA) and Bioanalysis. Three types of study samples were analyzed: lysate, dose, and media. Lysate samples were stored in their original 6-well plates. Dose and medium samples were stored in polypropylene tubes. All samples were stored at less than -70°C until analysis.
Before sample analysis, cell lysis solution (750 -1000 µL of 70% methanol / 30% ultra-pure H 2 O) was added to each well and sonicated for 10 minutes. The suspension in each well was transferred to a polypropylene deep well plate and evaporated to dryness using heated nitrogen gas. Dose and medium samples were Furthermore, SCDH showed an increase in the rate of Cu uptake and efflux in response to dose concentration consistent with that observed in SCRH. Figure 4B shows the effect of incubation time on Cu disposition in SCDH. An increase in incubation time resulted in a slight increase in Cu accumulation; however, the mass excreted in bile was similar among the incubation times evaluated. The rate of Cu uptake decreased from two to four hours of incubation in SCDH and thereafter remained constant; however, the rate of Cu efflux continued to decrease with increased incubation time.
This article has not been copyedited and formatted. The final version may differ from this version. Figure 5B shows the effect of incubation time on Cu disposition in SCDH. An increase in incubation time resulted in an increase in intracellular Cu accumulation but had no effect on the mass of Cu excreted in bile. The rate of Cu uptake and efflux decreased in response to incubation time.
Effect of L-000870810 on Hepatobiliary Disposition of Cu in SCH. The effect of L-

(a naphthyridine HIV integrase inhibitor) on the hepatobiliary disposition of
Cu was determined in SCRH, SCDH and SCHH at two concentrations (5 and 50 µM, 4 hour incubation) and the results are presented in Figure 6 and Table 1 . The results presented in Figure 6 show the intracellular accumulation and mass excreted in bile normalized to control values (no inhibitor) and expressed as % control. In SCRH, L-000870810 showed no effect on Cu accumulation or biliary excretion (mass excreted in bile) at either concentration in comparison to controls. L-000870810 showed no effect on intracellular accumulation of Cu in SCDH at either concentration ( Figure 6B (5 µM) showed some effect on biliary excretion; however, the differences failed to reach statistical significance. Table 1 shows the effect of L-000870810 on the rate of Cu uptake and efflux in SCRH, SCDH and SCHH. L-000870810 had no major effect on the rate of Cu uptake or efflux in SCRH. SCDH exposed to 5 µM L-00870810 showed an ca. 2.5-fold increase in the rate of Cu uptake in comparison to controls and a 2-fold increase in the rate of efflux in comparison to controls. An increase in the dose concentration to 50 µM L-00870810 also resulted in an increase in the rate of Cu uptake and efflux; however, this increase was not dose proportional. L-000870810 increased the rate of Cu uptake and efflux in SCHH only at the higher dose and showed more of an effect on the rate of Cu efflux than uptake.
This article has not been copyedited and formatted. The final version may differ from this version. (Petris et al., 2003) .
In addition to the role CTR1 plays in hepatic uptake of Cu, the intracellular homeostatic control is primarily achieved through the interaction of the Cu chaperone, ATOX1, with the Cu transporting ATPase, ATP7B (Walker et al., 2002) . The expression, localization and function of ATP7B has been extensively studied and characterized using in vitro models to understand ATP7B's role in the homeostatic control of Cu and its altered function in disease states. Under low Cu concentrations, ATP7B is localized to the trans-golgi network (TGN) where its primary function is to transport Cu across the golgi membrane for incorporation into ceruloplasmin and excretion across the basolateral membrane into the blood (Murata et al., 1995; Terada et al., 1995; Hellman et al., 2002) .
Results obtained in this study showed that SCRH were able to synthesize and secrete This article has not been copyedited and formatted. The final version may differ from this version. ATP7B also plays an essential role in the elimination of Cu through biliary efflux across the canalicular membrane (Lutsenko et al., 2002) . The exact mechanism by which ATP7B is involved in the transport of Cu across the canalicular membrane into bile is still the subject of debate (Schaefer et al., 1999; Forbes and Cox, 2000; Harada et al., 2000; Cater et al., 2006; Bartee and Lutsenko, 2007) . It is generally accepted that ATP7B does not localize to the plasma membrane to directly efflux Cu into the bile canaliculi.
Instead, ATP7B traffics to vesicles where ATOX1 delivers the Cu followed by a migration towards the canalicular membrane. Several theories have been developed to explain how ATP7B is recycled back to the TGN prior to vesicular fusion with the canalicular membrane and release of Cu. In the Long-Evans Cinnamon (LEC) rat, the rodent model of Wilson disease, incorporation of Cu into ceruloplasmin, as well as the biliary excretion of Cu, is restored when ATP7B is introduced in the liver via recombinant adenovirus-mediated gene delivery (Meng et al., 2004) . Thus, ATP7B appears to be involved in both Cu incorporation into ceruloplasmin and its excretion into bile. In addition to the LEC rat, the Bedlington terrier has been a useful model for understanding Cu disposition and toxicosis in dogs. In this species, copper toxicosis is manifested as an inherited disorder characterized by both a massive lysosomal Cu accumulation and an inefficient ability to excrete Cu into the bile (Harris, 2003; Klomp et al., 2003; Favier et al., 2005) . Western blot analysis was used to verify the expression of increased the expression levels of Atp7b in SCRH suggesting a protective mechanism by increasing the rate of Cu efflux from hepatocytes to bile.
Hepatocytes maintained in a collagen-sandwich configuration prolongs cell viability and reestablishes structurally and functionally normal bile canalicular networks with drug uptake, excretion and enzyme induction potential. Furthermore, SCH have proven to be a useful in vitro model to predict the in vivo biliary excretion of drug candidates (Liu et al., 1999; Ghibellini et al., 2007) . Based on the results presented in this study, SCH express the uptake and efflux transporters required for assessing the hepatobiliary disposition of Cu. The few functional studies reported in the literature that have measured Cu transport in an in vitro system used either plasma membrane vesicles or suspended hepatocytes which do not allow for the simultaneous assessment of both Cu uptake and efflux. In addition, studies have shown that the cell architecture in suspended hepatocytes is disrupted and transporters that normally reside in the canalicular membrane are internalized and non-functional (Hoffmaster et al., 2004) . Hepatic uptake and more importantly biliary excretion of Cu was observed in SCRH, SCDH and SCHH.
The most notable differences among the species evaluated in this study were the endogenous levels of Cu. In SCRH, SCDH and SCHH endogenous Cu was present at 17.2 ± 7.00, 490 ± 44.8 and 43.5 ± 15.8 ng/well, respectively. Thus, SCDH contained more than ten and twenty-five times the amount of Cu found in human and rat hepatocytes, respectively. The high Cu content found in SCDH may be attributed to a William's E and HMM) thus ruling out differences in endogenous Cu content is attributed to differences in media composition. In a study conducted by Matsuda et al., the effect of polaprezinc on Cu content in different organs of rats and beagle dogs was determined (Yamaguchi et al., 1996) . Prior to treatment, Cu content in 13 and 52 weekold male Sprague-Dawley rats were 3.56 ± 0.14 and 5.56 ± 0.24 µg/g, respectively (n=5).
In the same study, Cu content in untreated 13 and 52 week-old male beagle dogs were 57.32 ± 16.81 and 173.3 ± 109.7 µg/g, respectively. Based on these observations, dog liver contained fifteen to thirty times more Cu in comparison to rat liver. Thus, our findings are consistent with these results and suggest that dog liver sequester more Cu than rat livers. Normal Cu content in human liver is 6.2 µg/g (Linder, 1991) and is consistent with our findings that SCHH had approximately twice the Cu content as observed in SCRH. Even though the SCDH contained much higher Cu levels than the SCRH and SCHH, they were still able to respond to the exogenous Cu added to culture as seen by an increase in uptake and efflux with the increase in dose concentration and incubation time.
SCH were evaluated as an in vitro model to predict the effect L-000870810 has on hepatobiliary Cu disposition as observed in vivo (Vacca et al., 2007) . L-000870810 is a naphthyridine containing compound developed by Merck for the treatment of HIV via inhibition of HIV integrase. Following initial success in short-term monotherapy in naïve and treatment experienced HIV-1 infected patients, L-000870810 development was halted due to an observed toxicity in the liver and kidneys of dogs after long-term dosing (Little et al., 2005) . Although the exact mechanism of liver and kidney toxicity was not revealed, one criterion set forth for second generation inhibitors was, "no inhibition of Cu This article has not been copyedited and formatted. The final version may differ from this version. (Vacca et al., 2007) . Thus we investigated whether SCH could be used as an in vitro model to predict interactions between L-000870810 and Cu disposition in SCRH, SCDH and SCHH. L-000870810 had no effect on uptake or biliary efflux of Cu in SCRH; however, there was a dose dependent increase in the amount of Cu excreted in bile of SCDH and SCHH. These results may be useful in explaining the toxicity related effects of L-000870810 observed in dogs but not seen in rat. Interestingly, L-000870810 toxicity was only seen in dog, which displayed unusual characteristics in this study not seen with rat including a much higher endogenous hepatic Cu concentration and an increase in the rate of Cu uptake and efflux with increasing L-000870810 concentrations ( Figure 6 ). Although, the exact mechanism by which L-00870810 affects Cu disposition in dog, and possibly human, hepatocytes has not been determined. Possible mechanisms may include: an effect on the expression or interaction with CTR1 and/or ATP7B affecting the intracellular homeostatic control of Cu levels, interference with the intracellular Cu chaperones or some other mechanism that regulates the homeostatic control of intracellular Cu or its ability to chelate divalent cations (e.g., Mg 2+ ) and transport Cu into bile.
In conclusion, SCH have proven to be a model to assess the in vitro hepatobiliary disposition of Cu. The ability to measure both uptake and efflux in an intact system, allows SCH to serve as a useful model to further examine the role that transporters Δ Uptake
Δ Efflux
Copper (ng)
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